Dolutegravir was developed by GlaxoSmithKline for the treatment of HIV-infected adults and children over 12 years old. Its product TIVICAY was approved in China in 2016 and was approved for children’s indications in China in 2019. As of the first half of 2021, ViiV Healthcare BV is the only manufacturer in the Chinese Dolutegravir market.
According to CRI’s market research, the sales of Dolutegravir in the Chinese market have had an upward trend from 2016 to 2020. Due to the advantages of Dolutegravir, such as good tolerability, drug resistance, and convenience of taking drugs, its sales in the Chinese market have grown rapidly, from CNY0.2 million in 2016 to CNY3.14 million in 2017, with an annual growth rate of 1392.89%. In 2020, sales of Dolutegravir fell by 12.92%. The main reason for a decline in its sales is that the COVID-19 epidemic has impacted the hospital’s overall diagnosis and treatment business. Dolutegravir has a CAGR of 166.14% from 2016 to 2020.
CRI predicts the sales of Dolutegravir will increase from 2021 to 2025 with the increase in the number of AIDS patients. The number of surviving HIV-infected people in China increased from 958,000 in 2019 to 1.045 million in 2020, with a growth rate of 9%. The number of new infections shows an increasing trend. Therefore, sales of Dolutegravir used to treat HIV infection will continue to increase. In addition, with the effective alleviation of the COVID-19 epidemic, the sales of Dolutegravir will have a restorative growth from 2021 to 2025.
-The impact of COVID-19 on China’s Dolutegravir market
– Sales value of China’s Dolutegravir 2016-2020
– Competitive landscape of China’s Dolutegravir market
– Prices of Dolutegravir in China
– Prices of Dolutegravir in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dolutegravir market
– Prospect of China’s Dolutegravir market from 2021 to 2025